SIGA Technologiesの空売り状況は、投資家がSIGA Technologiesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

SIGA Technologies (NASDAQ:SIGA) 株価情報, 空売り情報

SIGA Technologies

SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.

SIGA Technologies Inc

On Thursday,&nbsp;the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) antiviral treatment TEPOXX (tecovirimat 200 mg capsules) for smallpox, mpox, cowpox, as well as complications following smallpox vaccination in adults and pediatric patients <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42761893/tepoxx-tecovirimat-approved-in-japan-for-the-treatment-of-orthopoxviruses" rel="noreferrer noopener">weighing at least 13 kg</a>.
TEPOXX is the first antiviral therapy for orthopoxviruses approved by Japan's drug regulator in collaboration with the Ministry of Health, Labour, and Welfare.&nbsp;&nbsp;
In partnership with Japan Biotechno Pharma, SIGA's exclusive distributor in Japan, SIGA has delivered an order of TEPOXX to help build Japan's strategic national stockpile.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40394363/in-nih-cosponsored-monkeypox-virus-study-in-congo-siga-technologies-antiviral-tecovirimat-did-not" rel="noreferrer noopener">In NIH-Cosponsored Mpox Virus Study In Congo, SIGA Technologies' Antiviral Tecovirimat Did Not Improve Lesion Resolution, Stock Tanks</a>
The Japanese approval is based on data from 15 clinical trials of oral TEPOXX in over 800 healthy volunteers, including a pivotal repeat-dose phase 1 pharmacokinetics (PK) trial involving 20 healthy volunteers conducted in Japan.
These studies showed no drug-related serious adverse events and quantifiable PK within efficacious dose ranges. Four pivotal studies in non-human primates (NHPs) and two pivotal studies in rabbits demonstrated that TEPOXX significantly reduced mortality and viral load.
TEPOXX is a highly targeted small-molecule antiviral that inhibits the VP37 protein found on the surface of all orthopoxviruses. By preventing the virus from exiting infected cells, TEPOXX slows the spread of the infection, enabling the immune system to clear the virus.
TPOXX is approved for smallpox in the U.S.&nbsp;and Canada. In the&nbsp;European Union and the UK, marketed as Tecovirimat-SIGA, it is approved&nbsp;for smallpox, mpox, and cowpox and to treat complications following smallpox vaccination.
Earlier this year, the National Institutes of Health's National Institute of Allergy and Infectious Diseases announced topline results from a preliminary analysis of the PALM 007 trial of<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40394363/in-nih-cosponsored-monkeypox-virus-study-in-congo-siga-technologies-antiviral-tecovirimat-did-not" rel="noreferrer noopener"> tecovirimat for mpox</a>.
The study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo with mpox who were administered SIGA's tecovirimat versus placebo, weighing <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534370/government-contract-win-may-improve-investor-sentiment-for-siga-tech-after-disappointing-trial-da" rel="noreferrer noopener">on the share price</a>.
Price Action: At last check Thursday, SIGA stock was up 3.01% at $6.19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42763569/why-tutor-perini-shares-are-rising-premarket-on-thursday" target="_blank" rel="noreferrer noopener">Gary Smalley Takes The Helm As Tutor Perini's CEO; Ronald Tutor Stays On As Executive Chairman</a></li>
</ul>

Biotech

News

Health Care

Movers

General

SIGA

Japan Approves SIGA Technologies Antiviral As First For Smallpox, Mpox

WIIM

SIGA Technologies shares are trading higher after the company announced TEPOXX was approved in Japan for the treatment of orthopoxviruses.

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpox.
Japan&nbsp;Biotechno Pharma Co., Ltd. engaged as exclusive distributor to supply TEPOXX to Japan's national stockpile. &nbsp;

SIGA Technologies Says TEPOXX (Tecovirimat 200 Mg Capsules) Has Received Regulatory Approval In Japan

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.2% on Monday.
Shares of Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) fell sharply in today's pre-market trading after a US jury reportedly found Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) did not breach Nuvia&#8217;s license agreement <a href="https://www.benzinga.com/quote/ARM">with the company</a>.
Arm Holdings shares fell 2.3% to $129.14 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Core Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) shares dipped 11% to $15.00 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares declined 10.8% to $8.53 in pre-market trading.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) declined 8.5% to $5.41 in pre-market trading.</li>
<li>Dnow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNOW#NYSE">DNOW</a>) fell 7.7% to $11.90 in pre-market trading.</li>
<li>DiamondRock Hospitality Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) fell 4.3% to $8.92 in pre-market trading.</li>
<li>NI Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NODK#NASDAQ">NODK</a>) fell 3.8% to $14.73 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ATXS

DNOW

NODK

QCOM

Arm Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) rose sharply in today's pre-market trading after the company announced it has entered into a definitive agreement for a strategic <a href="https://www.benzinga.com/24/12/42634166/rumble-stock-soars-on-775-million-investment-from-tether-what-to-know">investment of $775 million from Tether</a>.
Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) has agreed to purchase 103.33 million shares of Rumble Class A Common Stock at a price per share of $7.50, totaling $775 million in gross proceeds to Rumble.
Rumble shares jumped 43.3% to $10.31 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) gained 234% to $4.01 in pre-market trading.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) gained 88.6% to $3.32 in pre-market trading. Phio Pharmaceuticals, last week, announced a $1.15 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) climbed 82.3% to $0.4334 in pre-market trading after surging 63% on Friday. Edible Garden recently announced it experienced a 51% year-over-year increase in its preliminary Thanksgiving period sales.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) gained 60.9% to $0.8530 in pre-market trading. JIADE received Nasdaq notification letter regarding minimum bid price deficiency.</li>
<li>American Battery Technology Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABAT#NASDAQ">ABAT</a>) rose 44.1% to $1.60 in pre-market trading. On Friday, American Battery Technology priced its $5 million registered direct offering of 5 million shares at $1.00 per share.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) gained 30.9% to $3.60 in pre-market trading after jumping more than 36% on Friday.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) rose 28.8% to $0.9700 in pre-market trading after the company was awarded ISO/IEC 27001:2022 certification.</li>
<li>Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) gained 18% to $28.19 in pre-market trading. Honda Motor and Nissan Motor Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) have started talks for a potential merger.</li>
<li>Kodiak Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) rose 14.9% to $9.94 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares tumbled 28.9% to $0.0531 in pre-market trading after jumping 14% on Friday. Conduit Pharmaceuticals recently announced it entered an agreement with Sarborg to leverage AI and its cybernetics platform to evaluate key deliverables across multiple areas of operations.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) declined 25.7% to $0.6759 in pre-market trading after jumping around 101% on Friday.</li>
<li>Onfolio Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONFO#NASDAQ">ONFO</a>) fell 24.4% to $1.21 in pre-market trading. Onfolio Holdings announced a quarterly preferred stock cash dividend of 75 cents per share.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares fell 24.3% to $0.6703 in pre-market trading after declining 9% on Friday.</li>
<li>ConnectM Technology Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares dipped 20% to $0.83 in pre-market trading after falling 8% on Friday. ConnectM Technology Solutions, last week, announced a year-over-year increase in third-quarter revenue results.</li>
<li>TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) fell 19.2% to $1.94 in today's pre-market trading after jumping 97% on Friday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) dipped 17.8% to $0.2293 in pre-market trading after jumping 64% on Friday. Aptose Biosciences, last week, announced it was granted an extension to provide compliance evidence for a continued Nasdaq listing.</li>
<li>Core Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) fell 11% to $15.00 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares fell 10.8% to $8.53 in pre-market trading.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) fell 8.5% to $5.41 in pre-market trading.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/earnings/24/04/38307448/investor-sentiment-decreases-further-s-p-500-falls-for-fourth-straight-session&#8221;&gt;&lt;em&gt; Investor Sentiment Decreases Further, S&amp;P 500 Falls For Fourth Straight Session&lt;/em&gt;&lt;/a&gt;

Earnings

$USDT

ABAT

AILE

APTO

BNRG

CNTM

EDBL

HSDT

JDZG

LAES

NSANY

ONFO

PHIO

RELI

TPIC

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

SIGA Technologies shares are trading lower after interim results from the STOMP study showed that Tecovirimat did not improve the time to lesion resolution compared to placebo in adults with mild to moderate clade II Mpox.

<a href="https://www.niaid.nih.gov/news-events/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain">https://www.niaid.nih.gov/news-events/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain</a>
<h2>Study Examined Tecovirimat in Countries Affected by Global Clade II Mpox Outbreak</h2>
&nbsp;
The antiviral drug tecovirimat did not reduce the time to lesion resolution&nbsp;or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP). There were no safety concerns associated with tecovirimat.&nbsp;
Considering&nbsp;these definitive findings, the study's Data Safety and Monitoring Board (DSMB) recommended stopping further enrollment of participants who were being randomized to tecovirimat or placebo. As the study sponsor, the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) accepted the DSMB's recommendation.&nbsp;Given the lack of an efficacy signal, NIAID also closed enrollment into an open-label study arm for participants with or at elevated risk of severe disease that was not designed to estimate the drug's efficacy.&nbsp;

'NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution Or Pain'

SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported $10.00 million in sales this quarter. This is a 8.28 percent increase over sales of $9.23 million the same period last year.

SIGA Technologies Q3 EPS $0.02 Up From $(0.01) YoY, Sales $10.00M Up From $9.23M YoY

SIGA Enters Exclusive License Agreement With Vanderbilt University To Obtain A License To A Portfolio Of Preclinical Fully Human Poxvirus Monoclonal Antibodies

The contract was executed in response to a request from the Ministry of Health in Morocco to make the therapy available in the country and help prepare and protect its citizens against any potential mpox outbreak.
Tecovirimat is approved in the U.S., Canada, and the EU, and while it has also been available in Africa through clinical trials and as part of the World Health Organization&#39;s emergency use access protocol, this agreement marks SIGA&#39;s first commercial sale of TPOXX on the continent.

Contracts

SIGA Technologies Enters Agreement To Supply TPOXX (Tecovirimat) In Morocco

The World Health Organization announced a new strategic preparedness and response plan Monday in the fight against mpox, two weeks after declaring a public health emergency<a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal"> on the outbreak.</a>
What Happened: The WHO announced a new plan in its fight against the outbreak of mpox. The plan comes as several companies are<a href="https://www.benzinga.com/news/24/08/40439999/geovax-labs-stock-continues-to-surge-whats-going-on"> ramping up efforts</a> to launch or increase output of mpox vaccines and treatment options.
The <a href="https://www.who.int/news/item/26-08-2024-global-strategic-preparedness-and-response-plan-launched-by-who-to-contain-mpox-outbreak">plan </a>calls for $135 million in funding for the WHO response and for member states and partners. Among the partners are communities, researchers and the Africa Centres for Disease Control and Prevention.
Funding will help with surveillance, prevention, readiness and the response to fight outbreaks of mpox, the WHO said.
The WHO said it will take part in strategic vaccination efforts to focus on high-risk individuals, which includes health care workers and those with close contact to recent cases.
"The mpox outbreaks in the Democratic Republic of the Congo and neighboring countries can be controlled, and can be stopped," WHO Director-General Dr. Tedros Adhanom Ghebreyesus said. 
"Doing so requires a comprehensive and coordinated plan of action between international agencies and national and local partners, civil society, researchers and manufacturers, and our Member States."
A virtual scientific conference will be held on Aug. 29 and Aug 30 to share mpox research and outbreak control goals from the WHO, Africa CDC and the National Institute of Allergy and Infectious Diseases.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/08/40559658/diagnostic-giants-labcorp-roche-to-ramp-up-testing-capacity-amid-global-concerns-over-new-mpox-str">Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain</a>
Why It's Important: The six-month plan is viewed as the critical step in stopping mpox outbreaks from spreading further or faster.
On Monday, Germany announced it will donate 100,000 mpox vaccine doses from its stockpile to help with the outbreak prevention, as reported by Reuters. Germany will keep a minimum stock of mpox vaccines, the report said. 
There have been 3,326 confirmed cases of mpox in Africa in 2024, with 590 deaths across 12 countries, according to the Africa Centres for Disease Control and Prevention, as <a href="https://thehill.com/policy/healthcare/4847877-who-releases-mpox-outbreak-plan/">reported </a>by The Hill. A total of 17,979 suspected mpox cases have been reported. 
Shares of companies that have mpox vaccines or treatments have been highly volatile over the last two weeks. The list includes Bavarian Nordic (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNRY#OTC">BVNRY</a>) and Emergent Biosolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), both of which have WHO-recommended vaccines
GeoVax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) and SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) have also been highly volatile. GeoVax has a mpox vaccine in clinical development. SIGA Technologies has Tpoxx, which is a treatment for mpox.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40554882/tonix-pharma-collaborates-with-worlds-largest-vaccine-manufacturer-for-mpox-vaccine">Tonix Pharma Collaborates With World&#8217;s Largest Vaccine Manufacturer For Mpox Vaccine</a></li>
</ul>
Illustration via Shutterstock.

Global

BVNRY

GOVX

WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped'

On Wednesday, SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>)&nbsp;announced a new contract with the&nbsp;U.S. Department of Defense&nbsp;(DOD) to procure approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40493842/siga-announces-new-contract-awarded-by-u-s-department-of-defense-for-the-procurement-of-9-million-" rel="noreferrer noopener">$9 million&nbsp;of TPOXX</a>.
This award is comprised primarily of oral TPOXX, with a small amount of intravenous (IV) TPOXX, and represents the third procurement contract award from the DOD over the past three years.
The company also received approximately&nbsp;$27 million&nbsp;to develop the post-exposure Prophylaxis indication for oral TPOXX.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/24/08/40446949/mpox-variant-sparks-global-concern-as-europe-china-ramp-up-screening" rel="noreferrer noopener">Mpox Variant Sparks Global Concern As Europe, China Ramp Up Screening</a>.
Inclusive of this award, SIGA currently has approximately $154 million of outstanding oral and IV TPOXX&nbsp;orders, more than 85% of which were generated within the past three months.
Edison report adds that SIGA continues to advance its growth strategy, with recent contract wins from BARDA and the Department of Defense significantly boosting its order book.
The company is set to deliver IV TPOXX under orders from July 2023 ($25 million), and August 2022 ($8.4 million, of which $17.8 million from a $26 million order was already delivered in the first half of 2024).
These are part of approximately $155 million in outstanding TPOXX (oral and IV) orders.
SIGA anticipates delivering the remaining August 2022 IV TPOXX order and 80% of the BARDA oral TPOXX order in the second half of 2024.
While delivery timeline details are yet to be disclosed, Edison Group&#8217;s report notes that new DoD order to start at least being partially serviced in fiscal year 2025.
Recently, the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases (NIAID) announced topline results from a preliminary analysis of the PALM 007 trial of<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40394363/in-nih-cosponsored-monkeypox-virus-study-in-congo-siga-technologies-antiviral-tecovirimat-did-not" rel="noreferrer noopener"> tecovirimat for mpox</a>.
NIAID reported that the study did not meet its primary endpoint of a statistically significant improvement in time to lesion resolution within 28 days post-randomization for patients in the Democratic Republic of the Congo with mpox who were administered SIGA&#8217;s tecovirimat versus placebo, weighing on the share price.
Edison analysts expect an improvement in investor sentiment with the recent DoD contract win.
&#8220;We maintain that mpox continues to be an opportunity for SIGA on the heels of the WHO&nbsp;declaration of a global health emergency,&#8221; the analysts added.
Price Action: SIGA stock is up 4.07% at $9.72 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40528702/europe-approves-modernas-rsv-vaccine-for-adults-60-and-over" target="_blank" rel="noreferrer noopener">Europe Approves Moderna&#8217;s RSV Vaccine For Adults 60 And Over</a>.</li>
</ul>

Government

Government Contract Win May Improve Investor Sentiment For SIGA Tech After Disappointing Trial Data: Analyst

SIGA Technologies shares are trading higher after the company announced it was awarded a new contract by the U.S. Department of Defense for the procurement of $9 million worth of TPOXX.

SIGA Technologies, Inc. (SIGA) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract with the&nbsp;U.S. Department of Defense&nbsp;(DOD) for the procurement of approximately $9 million&nbsp;of TPOXX&#xAE; (Contract number: W911SR24C0030). This award is comprised primarily of oral TPOXX&#xAE;, with a small amount of intravenous (IV) TPOXX&#xAE;, and represents the third procurement contract award from the DOD over the past three years. &nbsp;
SIGA has been collaborating with the DOD's&nbsp;Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop the Post-exposure Prophylaxis (PEP) indication for oral TPOXX&#xAE;, and this work has been supported by a development contract with a value of approximately&nbsp;$27 million&nbsp;(Contract number: MCDC1901-001-2019-400) as well as a Cooperative Research and Development Agreement.

SIGA Awarded Contract By U.S. Department Of Defense For The Procurement Of $9M Of TPOXX

Authorities in Europe and China are expediting screening for a <a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal">deadly new version </a>of mpox that has spread across regions of Africa and has been found in Europe.
The European Center for Disease Prevention and Control on Friday raised its risk assessment for mpox and forecasted more imported cases after a new strain called clade I was confirmed in Sweden, <a href="https://www.axios.com/2024/08/19/mpox-mobilization-intensifies-outside-of-africa">Axios</a> reported.
Pakistan&#8217;s health ministry reported Friday that it identified an mpox case and was conducting sequencing to determine if it is the new strain.
China&#8217;s customs administration said it would look for signs of mpox in people and goods entering the country over the next six months, the state-run, English-speaking news TV channel CTGN reported.
According to the <a href="https://www.cdc.gov/cfa-modeling-and-forecasting/mpox-transmission-technical-brief/index.html">CDC</a>, the Democratic Republic of the Congo&#8217;s ongoing mpox outbreak, driven by the more transmissible and severe Clade I virus, involves multiple transmission modes, including household and sexual exposures, with 70% of cases in children under 15.
Read Also: <a href="https://www.benzinga.com/news/24/08/40444353/virax-biolabs-shares-climb-with-mpox-cases-what-to-know">Virax Biolabs Shares Climb With Mpox Cases: What To Know</a>
More than 16,000 new cases and 511 deaths have been reported in Africa this year, and nine countries have reported confirmed new cases of mpox in recent weeks.
The World Health Organization last week declared mpox a global health emergency, acknowledging that it would likely spread across Africa and outside the continent. The organization is working with countries and drugmakers on vaccine donations.
Clade I is different from the less severe Clade II strain of mpox that caused the global outbreak in 2022, but they both share similar flu-like symptoms and produce a rash that at first resembles pimples or blisters.
In the U.S.,&nbsp;the Centers for Disease Control and Prevention has told doctors to watch out for the new mpox strain, but it also said that the risk to the public is very low.
Two vaccines &#8212; Jynneos, made by Bavarian Nordic (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNRY#OTC">BVNRY</a>) and LC16, from KM Biologics &#8212; have received emergency authorizations. Bavarian Nordic has asked the European Union&#8217;s drug regulator to expand Jynneos&#8217; use to 12- to 17-year-olds, an age group especially at risk from clade 1.
A National Institutes of Health study showed the smallpox antiviral drug tecovirimat, which is made by SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) did not lower the duration of mpox lesions among children and adults with Clade I mpox in the DRC.
Price Action: Shares of Bavarian Nordic were down 1.79% to $13.70 as SIGA declined 0.29% to $10.46 at the time of publication Monday, while most of the exchange-traded funds that cover the segment gained.
<ul>
<li>Amplify Treatments, Testing and Advancements ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GERM#NYSE">GERM</a>) fell 0.35%.</li>
<li>Roundhill Acquirers Deep Value ETF ARCA: DEEP) gained 0.62%.</li>
<li>Invesco NASDAQ Future Gen 200 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQS#NASDAQ">QQQS</a>) picked up 0.80%.</li>
<li>VictoryShares Small Cap Free Cash Flow ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFLO#NASDAQ">SFLO</a>) went up 0.93%.</li>
<li>First Trust Dow Jones Select MicroCap Index Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDM#NYSE">FDM</a>) rose 0.46%.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40439999/geovax-labs-stock-continues-to-surge-whats-going-on">GeoVax Labs Stock Continues To Surge: What&#8217;s Going On?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Asia

ETFs

DEEP

First Trust/First Trust Dow Jones Select MicroCap Index Fund

ETFMG Treatments Testing and Advancements ETF

GERM

QQQS

SFLO

Mpox Variant Sparks Global Concern As Europe, China Ramp Up Screening

So-called &#8220;bull traps&#8221; often frustrate traders, as they did on Wednesday, snaring shares of SIGA Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) — and there may be <a href="https://www.benzinga.com/money/bull-trap-vs-bear-trap">another one today</a>.
That's why it&#8217;s our ‘<a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>'.
SIGA shares have been very active because of a surge in Mpox (The World Health Organization ceased using the term Monkey Pox in November 2022 to reduce the stigma and association with monkeys). 
SIGA produces treatments for this disease. The New York-based company released disappointing trial data for a drug to treat Mpox on Thursday, Aug. 15, causing the stock to fall almost 20%. However, it jumped more than 15% early Friday.
Read Also: <a href="https://www.benzinga.com/news/24/08/40402519/emergent-biosolutions-bavarian-nordic-geovax-and-siga-technologies-shares-are-making-big-moves-thurs">Emergent Biosolutions, Bavarian Nordic, GeoVax And SIGA Technologies Shares Are Making Big Moves Thursday</a>
What Is A Bull Trap? A bull trap is akin to a false breakout.  It looks like a stock is going to break out and keep moving higher. But the sellers quickly overpowered the buyers and pushed the stock back below the resistance.
Resistance is a large group of traders and investors who are trying to sell shares close to the same price. As you can see on the chart, there has been resistance for SIGA around $10.50.
Sometimes when a stock reaches resistance it reverses and heads lower. This happened with SIGA in late July and early May.
This occurs when some of the people who created the resistance with their sell orders become concerned that other sellers will undercut them. They know that the buyers will go to whoever is willing to sell at the lowest price.
So, they reduce the prices they are willing to sell at. Other concerned sellers see this and do the same. It results in a snowball effect that pushes the price lower.
But sometimes the stock ‘breaks out' and moves above the resistance.
Breakouts can signal a bullish dynamic. It could mean that the traders and investors who created the resistance with their sell orders have either finished or canceled.
This means a large amount of the supply of shares is gone. If buyers enter the market, they will have a difficult time finding people to sell shares to them.
As a result, they will need to increase the prices they are willing to pay or the sellers won't be interested. This price action could force the shares into a new uptrend.
Sometimes the shares trade above the resistance and it looks like it's a breakout. But it's a ‘head fake'. The sellers have just been on the sidelines.
They come back into the market, overpower the buyers, and push the price lower. This is the ‘false breakout' or ‘bull trap'.
But savvy traders can often profit from these dynamics by going from long to short. &nbsp;Bull traps can be a good contrarian signal.
They tend to be followed by meaningful moves lower. SIGA may be about to enter a downtrend.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40419054/gold-prices-hit-all-time-highs-of-2-500-as-traders-jump-on-rate-cut-train-mining-stocks-on-the-mov">Gold Prices Hit All-Time Highs Of $2,500 As Traders Jump On Rate-Cut Train: Mining Stocks On The Move Friday</a></li>
</ul>
Image: Flickr

Short Ideas

Technicals

Stock Of The Day: Bull Trap Snares SIGA Technologies On Heels Of Mpox Study

U.S. stocks were mixed, with the Dow Jones index falling around 0.1% on Friday.
Shares of H&amp;R Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) rose sharply during Friday's session after the company reported better-than-expected fourth-quarter financial results and issued <a href="https://www.benzinga.com/news/earnings/24/08/40407075/h-r-block-q4-earnings-revenue-beat-eps-beat-strong-guidance-1-5b-buyback-stock-up-9">FY25 guidance above estimates.</a>
H&amp;R Block reported quarterly earnings of $1.89 per share which beat the analyst consensus estimate of $1.74. The company reported quarterly sales of $1.063 billion which beat the analyst consensus estimate of $1.028 billion.
Also, the company announced a quarterly dividend increase and $1.5 billion share repurchase authorization.
H&amp;R Block shares jumped 16.4% to $66.73 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares jumped 25% to $10.82. Shares of vaccine and mpox-related stocks traded higher after the WHO declared it a global health emergency.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) surged 16.4% to $36.52. AST SpaceMobile recently said its first five commercial satellites are on target for orbital launch in the first half of September.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 16% to $6.76. Today, the company said it has successfully packed and shipped two Mars-bound spacecraft to Cape Canaveral, FL, in readiness for launch.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) gained 16% to $2.520 after the company announced that its first hyperspectral satellite, Tanager-1, along with 36 SuperDoves (Flock 4BE), will launch on the Transporter-11 rideshare mission with SpaceX on August 16.</li>
<li>Jumia Technologies AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JMIA#NASDAQ">JMIA</a>) rose 14.8% to $5.63. Jumia announced completion of at-the-market offering.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 14.6% to $0.8482. Cantor Fitzgerald analyst Andres Sheppard reiterated Polestar Automotive with an Overweight and maintained a $3 price target.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) gained 14.6% to $11.01.</li>
<li>Ambipar Emergency Response (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBI#NYSE">AMBI</a>) climbed 10.5% to $5.99.</li>
<li>Treace Medical Concepts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) rose 9.2% to $6.53.</li>
<li>CI&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) shares gained 7.4% to $7.25 after the company reported better-than-expected second-quarter financial results.</li>
<li>QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) gained 7.1% to $12.15.</li>
<li>Cellebrite DI Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NYSE">CLBT</a>) rose 6.7% to $15.96. Cellebrite, on Thursday, reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
<li>JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) gained 5.5% to $28.51.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) rose 4.9% to $83.44 after multiple analysts raised their price targets on the stock following Thursday&#8217;s earnings report.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40417110/jim-cramer-this-financial-stock-is-a-buy-core-scientific-is-a-very-overvalued-situation"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40417110/jim-cramer-this-financial-stock-is-a-buy-core-scientific-is-a-very-overvalued-situation">Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A &#8216;Very Overvalued Situation&#8217;</a></li>
</ul>

Intraday Update

AMBI

ASTS

BABA

CINT

CLBT

JMIA

PSNY

RKLB

TMCI

H&R Block Posts Upbeat Earnings, Joins Alibaba Group, CI&T And Other Big Stocks Moving Higher On Friday

<a href="https://www.ecdc.europa.eu/en/news-events/ecdc-recommends-enhancing-preparedness-more-imported-cases-clade-i-mpox-highly-likely" title="https://www.ecdc.europa.eu/en/news-events/ecdc-recommends-enhancing-preparedness-more-imported-cases-clade-i-mpox-highly-likely">https://www.ecdc.europa.eu/en/news-events/ecdc-recommends-enhancing-preparedness-more-imported-cases-clade-i-mpox-highly-likely</a>

ECDC Warns of Likely Mpox Cases in EU/EEA from Africa, But Low Risk of Sustained Transmission with Quick Diagnosis and Control

U.S. stocks traded higher toward the end of trading, with the S&amp;P 500 gaining around 1.5% on Thursday.
The Dow traded up 1.23% to 40,501.91 while the NASDAQ jumped 2.28% to 17,584.56. The S&amp;P 500 also rose, gaining, 1.52% to 5,538.34.
Check This Out: <a href="https://www.benzinga.com/news/24/08/40391883/wall-streets-most-accurate-analysts-spotlight-on-3-materials-stocks-with-over-4-dividend-yields"> Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Materials Stocks With Over 4% Dividend Yields</a>
Leading and Lagging Sectors Consumer discretionary shares climbed by 2.9% on Thursday.
In trading on Thursday, real estate shares fell 0.4%.
Top Headline
Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) reported downbeat sales for its fiscal first quarter.
The Jack Ma co-founded e-commerce giant reported fiscal first-quarter 2024 revenue growth of 4% year-on-year to $33.47 billion, missing the analyst consensus estimate of $34.81 billion. Adjusted earnings per ADS of $2.26 beat the analyst consensus estimate of $2.13.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cingulate Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) shares shot up 147% to $4.5802 after the company was granted European patent No. 3261625 for CTx-1301, its lead asset for the treatment of ADHD.</li>
<li>Shares of AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) got a boost, surging 47% to $30.53 after the company said its first five commercial satellites are on target for orbital launch in the first half of September.</li>
<li>Gambling.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAMB#NASDAQ">GAMB</a>) shares were also up, gaining 26% to $11.12 following better-than-expected second-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Turnstone Biologics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) shares dropped 59% to $0.8975 after the company reported worse-than-expected second-quarter EPS results.</li>
<li>Shares of SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) were down 26% to $8.82 after the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases announced topline results from a preliminary analysis of the PALM 007 trial of Tecovirimat for Monkeypox virus did not meet its primary endpoint.</li>
<li>Terran Orbital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>) was down, falling 41% to $0.2363. Lockheed Martin announced plans to acquire Terran Orbital.</li>
</ul>
Commodities In commodity news, oil traded up 1.4% to $78.09 while gold traded up 0.6% at $2,493.80.
Silver traded up 4.1% to $28.46 on Thursday, while copper rose 2.7% to $4.1490.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.15%, Germany's DAX rose 1.66% and France's CAC 40 rose 1.23%. Spain's IBEX 35 Index rose 1.23%, while London's FTSE 100 rose 0.80%.
The British economy grew by 0.9% year-over-year in the second quarter, recording the biggest annual growth rate since the third quarter of 2022. Labor productivity in the UK increased 0.3% on quarter during the second quarter. The UK&#8217;s trade deficit narrowed to £5.32 billion in June versus a revised £5.77 billion in the earlier month. Industrial production in the UK climbed 0.8% month-over-month for June.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 jumping 0.78%, Hong Kong's Hang Seng Index falling 0.03% and China's Shanghai Composite Index gaining 0.94%.
Industrial production in Japan fell by 4.2% month-over-month during June, while Japanese economy expanded by 3.1% on an annualized basis in the second quarter. China&#8217;s retail sales climbed by 2.7% year-over-year in July versus market estimates of 2.6%. China's industrial production rose by 5.1% year-over-year in July.
Economics
<ul>
<li>U.S. retail sales gained 1% month-over-month in July versus a revised 0.2% decline in June and higher than market estimates of a 0.3% gain.</li>
<li>The Philadelphia Fed Manufacturing Index declined to -7 in August from 13.9 in July and versus market estimates of 7.</li>
<li>The NY Empire State Manufacturing Index rose to -4.7 in August, notching the highest level in six months.</li>
<li>Export prices increased 0.7% month-over-month in July, while import prices rose 0.1%.</li>
<li>U.S. initial jobless claims declined by 7,000 to 227,000 in the week ending August 10, versus market estimates of 235,000.</li>
<li>U.S industrial production declined by 0.6% from the prior month in July compared to a revised 0.3% gain in June.</li>
<li>The NAHB/Wells Fargo Housing Market Index declined to 39 in August, recording the lowest level so far in 2024.</li>
<li>Total business inventories increased by 0.3% month-over-month in June compared to a 0.5% rise in the earlier month.</li>
<li>U.S. natural-gas supplies fell 6 billion cubic feet during the week ended Aug. 9.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/analyst-ratings/downgrades/24/08/40393124/this-snowflake-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday">This Snowflake Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday</a>

Equities

Eurozone

Commodities

CING

GAMB

LLAP

TSBX

Crude Oil Gains Over 1%; Alibaba Posts Weak Revenue

Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization&nbsp;declared a public health emergency in response to an <a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal">mpox outbreak in Africa</a>.
What Happened: WHO Director-General Tedros Adhanom Ghebreyesus determined this week that the recent surge of mpox, previously known as monkeypox, across a growing number of countries in Africa constitutes a public health emergency of international concern under International Health Regulations.
&#8220;The emergence of a new clade of mpox, its rapid spread in eastern DRC, and the reporting of cases in several neighbouring countries are very worrying. On top of outbreaks of other mpox clades in DRC and other countries in Africa, it's clear that a coordinated international response is needed to stop these outbreaks and save lives,&#8221; the WHO Director-General <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">said</a>.
Several stocks surged on the news Wednesday including Emergent Biosolutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), which owns one of two vaccines that have been recommended by the Centers for Disease Control and Prevention (CDC): ACAM2000. Bavarian Nordic&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BVNRY#OTC">BVNRY</a>) JYNNEOS is the other CDC recommended vaccine for mpox.
See Also: <a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal">WHO Declares Mpox Public Health Emergency: &#8216;Coordinated International Response Essential&#8217; To Halt Outbreak</a>
Shares of GeoVax Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) and SIGA Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) also traded higher on Wednesday, but they are moving in different directions Thursday. 
Geovax Labs&nbsp;is a clinical-stage biotechnology company engaged in developing immunotherapies and vaccines against cancers and infectious diseases.&nbsp;The company previously published information&nbsp;in&nbsp;peer-reviewed journals suggesting its vaccines help prevent mpox. GeoVax shares were up approximately 83% over the past week at the time of writing.
SIGA Technologies&nbsp;is a commercial-stage pharmaceutical company focused on the health security market. The company&#8217;s lead product is TPOXX (tecovirimat), an orally administered antiviral drug for the treatment of human smallpox disease.&nbsp;Mpox is in the same virus family as smallpox, but&nbsp;it causes milder symptoms.
SIGA Technologies shares soared on Wednesday, but the stock is giving back all of its gains on Thursday after&nbsp;the National Institute of Allergy and Infectious Diseases announced top-line results from a preliminary analysis of a trial testing TPOXX for mpox virus did not meet its primary endpoint.
Although the study did not meet statistical significance, SIGA said results suggest TPOXX provides clinical benefit compared to placebo in patients who are treated early and in patents with severe disease.
&#8220;We believe these data warrant further investigation and support our view that post exposure prophylaxis will be vital for treatment of severe cases of mpox and all cases of smallpox,&#8221; said Dennis Hruby, chief scientific officer of SIGA Technologies.
SIGA noted that additional studies are being conducted by trial sponsors around the world. These clinical trials are expected to help the company gain a deeper understanding of the potential for TPOXX to benefit patients with mpox.&nbsp;
Related Link: <a href="https://www.benzinga.com/general/biotech/24/08/40394363/in-nih-cosponsored-monkeypox-virus-study-in-congo-siga-technologies-antiviral-tecovirimat-did-not">In NIH-Cosponsored Monkeypox Virus Study In Congo, SIGA Technologies&#8217; Antiviral Tecovirimat Did Not Improve Lesion Resolution, Stock Tanks</a>
EBS, BNVRY, GOVX, SIGA Price Action: At publication time, Emergent Biosolutions shares were up 12.3% at $8.50, Bavarian Nordic shares were down 9.77% at $12.28, Geovax shares were up 13.5% at $3.69 and SIGA shares were down 29.4% at $8.45, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Emergent Biosolutions, Bavarian Nordic, GeoVax And SIGA Technologies Shares Are Making Big Moves Thursday: What's Going On?

Siga Technologies ( ($SIGA) ) has released its Q3 earnings. Here is a breakdown of the information Siga Technologies presented to its investors. SI...

SIGA Technologies Reports Strong Earnings and Growth

First mpox case linked to African outbreak reported in U.S.

SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket

SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook

SIGA Technologies Vs. Emergent BioSolutions: Product Portfolio And Future Outlook

The antiviral drug tecovirimat, from Siga Technologies (SIGA), did not reduce the time to lesion resolution or have an effect on pain among adults ...

NIH study finds Siga's tecovirimat did not improve Mpox resolution or pain

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – Frequency Electronics&nbsp;(FEIM)&nbsp;up...

Closing Bell Movers: Dave & Busters down 11% after Q3 miss

Siga Technologies (SIGA)' antiviral treatment Tepoxx, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as wel...

Siga Technologies approved in Japan for treatment of orthopoxviruses

SIGA wins Japan approval for mpox therapy Tepoxx

Check out this morning's top movers from around Wall Street, compiled by The Fly.&nbsp; HIGHER – Topgolf Callaway (MODG) up 8% after Jefferies upgr...

Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint

APDN

ARCO

BVNKF

CMRX

CODX

FEIM

FIGS

GOOG

GOOGL

HOOK

JOBY

MAMA

MIND

MODG

NMRA

PLAY

RCKT

RHHBF

RHHBY

SFIX

SPWH

SYNA

TNXP

Legal

Press Releases

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating SIGA Technologies, Inc. for potential violations of federal securities laws

SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies

SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman

Bragar Eagel & Squire, P.C. Is Investigating CSX, Stride, and SIGA and Encourages Investors to Contact the Firm

SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024

Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced

Comments

SIGA Technologies

空売り

SIGA Technologies (NASDAQ:SIGA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル